Cargando…

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [(177)Lu]Lu-PP-F11N

The inhibition of the mammalian target of rapamycin complex 1 (mTORC1) by everolimus (RAD001) was recently shown to enhance the tumor uptake of radiolabeled minigastrin. In this paper, we investigate if this finding can improve the in vivo therapeutic response to [(177)Lu]Lu-PP-F11N treatment. The N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grzmil, Michal, Imobersteg, Stefan, Blanc, Alain, Frank, Stephan, Schibli, Roger, Béhé, Martin P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708304/ https://www.ncbi.nlm.nih.gov/pubmed/34959437 http://dx.doi.org/10.3390/pharmaceutics13122156

Ejemplares similares

Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [(177)Lu]Lu-PP-F11N
por: Grzmil, Michal, et al.
Publicado: (2020)

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin (177)Lu-PP-F11N
por: Grob, Nathalie M., et al.
Publicado: (2021)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Signaling Network Response to α-Particle–Targeted Therapy with the (225)Ac-Labeled Minigastrin Analog (225)Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors
por: Qin, Yun, et al.
Publicado: (2023)

Oxidant and Antioxidant Effects of Gentisic Acid in a (177)Lu-Labelled  Methionine-Containing Minigastrin Analogue
por: Trindade, Victoria, et al.
Publicado: (2020)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
por: Khan, Mohid S., et al.
Publicado: (2021)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [(177)Lu]Lu-DOTA-TATE in Lewis rats
por: Zellmer, Johannes, et al.
Publicado: (2020)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
por: Hooijman, Eline L., et al.
Publicado: (2022)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

SUN-334 Evaluation of the CCK-2 Receptor Agonist (177)Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma: Results of a Phase 0 "Lumed" Study
por: Rottenburger, Christof, et al.
Publicado: (2019)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

Targeted Tumor Therapy with Radiolabeled DNA Intercalator: A Possibility? Preclinical Investigations with (177)Lu-Acridine
por: Ghosh, Subhajit, et al.
Publicado: (2020)

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with (68)Ga and (177)Lu as Potential Theranostic Agents
por: Salvanou, Evangelia-Alexandra, et al.
Publicado: (2022)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
por: Tschan, Viviane J., et al.
Publicado: (2022)

Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
por: Palmer, Jayne, et al.
Publicado: (2020)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model
por: Shim, Kyuhwan, et al.
Publicado: (2023)

Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
por: Monserrat Fuertes, Teresa, et al.
Publicado: (2023)

Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with (68)Ga and (177)Lu as Potential Theranostic Agent for Colon Cancer
por: Leonte, Radu Anton, et al.
Publicado: (2021)

Development of (177)Lu-phytate Complex for Radiosynovectomy
por: Yousefnia, Hassan, et al.
Publicado: (2013)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC
por: Kramer, Vasko, et al.
Publicado: (2020)

Promising potential of [(177)Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
por: Guzik, Patrycja, et al.
Publicado: (2020)

[(177)Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
por: Tönnesmann, Roswitha, et al.
Publicado: (2019)

Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [(177)Lu]Lu-Satoreotide Tetraxetan and the Agonist [(177)Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST(2)-Positive Tumours
por: Plas, Pascale, et al.
Publicado: (2022)

Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
por: Grzmil, Michal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ciovg494uej5cbo08e5b27qnki